보조생식기술 시장 예측(-2030년) : 제품별, 시술별, 기술별, 최종사용자별, 지역별 세계 분석

According to Stratistics MRC, the Global Assisted Reproductive Technology (ART) Market is accounted for $29.01 billion in 2023 and is expected to reach $57.99 billion by 2030 growing at a CAGR of 10.4% during the forecast period. Assisted Reproductive Technology (ART) describes a variety of medical treatments intended to help individuals or couples become pregnant in cases where conventional methods are not successful. Intrauterine insemination (IUI), in vitro fertilization (IVF), and fertility drugs are all included under this general term. Moreover, reproductive medicine has changed dramatically as a result of ART, which gives hope to those who are infertile or have trouble getting pregnant.

According to the data published on female infertility in the National Library of Medicines in December 2022, globally, 11% of women who had a previous live birth were unable to have another, and 2% of women aged 20 to 44 were unable to have any live births at all.

Market Dynamics:

Driver:

Growing rates of infertility

Infertility rates are rising, and the causes are largely related to modern lifestyles characterized by high levels of stress, sedentary behavior, and environmental variables. Additionally, medical disorders like endometriosis and polycystic ovarian syndrome (PCOS) greatly raise the incidence of infertility. The need for assisted reproductive technology (ART) is growing as more people and couples struggle to conceive naturally, highlighting these interventions as essential remedies for fertility problems.

Restraint:

Restricted success rates

Even though success rates for ART procedures-particularly in vitro fertilization-have increased due to technological advancements, pregnancy is not a given with these procedures. Furthermore, the effectiveness of these interventions may be limited by individual differences in response to treatments as well as by age and underlying medical conditions. For those considering ART, the fact that there are inherent uncertainties and varying success rates continues to be a major deterrent.

Opportunity:

Increasing cryopreservation's uses

Reproductive materials, such as eggs, sperm, and embryos, can have their viability extended through cryopreservation techniques like vitrification. Moreover, better synchronization with people's life decisions and circumstances is made possible by this. With the ability to store fertility for later use, cryopreservation's growing applications help people plan their families with more flexibility.

Threat:

Multiple pregnancy risks

The health of the mother and fetus are at risk due to the possibility of multiple pregnancies that are linked to certain ART procedures. Furthermore, preterm birth and low birth weight are two complications that increase health risks for mothers and their unborn children when they result from multiple pregnancies. In the field, reducing these risks without sacrificing high success rates is an ongoing challenge.

COVID-19 Impact:

The market for assisted reproductive technologies (ART) has been impacted by the COVID-19 pandemic. One could argue that the industry suffered a temporary setback when lockdowns and restrictions on non-essential medical procedures caused a temporary decline in fertility treatments. Nevertheless, there has been a noticeable uptick in demand for ART services as healthcare systems have adjusted to the new normal. Due to people re-evaluating their priorities and perhaps becoming more interested in family planning, the pandemic brought attention to the significance of reproductive health. Furthermore, improvements in virtual consultations and telehealth emerged as a benefit, providing a more convenient and approachable method of fertility treatment.

The In Vitro-fertilization (IVF) segment is expected to be the largest during the forecast period

In vitro fertilization (IVF) is the market segment with the largest share within Assisted Reproductive Technologies (ART). During in vitro fertilization (IVF), an egg is fertilized with sperm outside of the body, and the resultant embryo is then inserted into the uterus. Due to its adaptability and high success rates, this technique has become very popular and is now the preferred choice for singles and couples dealing with infertility issues. Moreover, when it comes to male factor infertility, fallopian tube disorders, and infertility that remains unexplained, infertility treatment with IVF is especially successful.

The Fertility Clinics segment is expected to have the highest CAGR during the forecast period

The market segment with the highest CAGR is fertility clinics. Providers of assisted reproductive technologies (ART), such as IVF and IUI, as well as other fertility treatments, are the focus of fertility clinics. They also offer complete reproductive healthcare services. In addition, the fertility clinic market has experienced strong growth due to the rising demand for these specialized services as well as improvements in ART procedures and technology. Additionally, a committed and targeted approach to reproductive care is provided by fertility clinics, which attract individuals and couples looking for in-depth knowledge of infertility treatments.

Region with largest share:

The largest share of the market for assisted reproductive technology (ART) worldwide is predicted to go to the European region. Well-established healthcare systems and a growing acceptance of fertility treatments are features of European nations like the United Kingdom, Germany, France, and Spain. A vast array of ART procedures are supported by the region's progressive regulatory frameworks, skilled reproductive specialists, and network of cutting-edge fertility clinics. Furthermore, Europe is still a major player in the global ART market, offering a wide range of reproductive services and encouraging improvements in the field of reproductive medicine.

Region with highest CAGR:

In the global assisted reproductive technology (ART) market, the Asia-Pacific region is projected to have the highest CAGR. This region, which includes China, India, and Japan, has seen a notable increase in the demand for reproductive treatments. The high growth in Asia-Pacific is attributed to a number of factors, including rising rates of infertility, rising acceptance of assisted reproductive technologies, and advancements in healthcare infrastructure. Additionally, encouraging government programs and shifting public perceptions of family planning are factors driving the rapid expansion of the ART market in Asia-Pacific.

Key players in the market:

Some of the key players in Assisted Reproductive Technology (ART) market include Ferring B.V., Apollo Hospitals Enterprise Ltd., INVO Bioscience, Laboratoire CCD, Nidacon International AB, Fujifilm Holdings Corporation, Bloom Fertility Centre, Inception Sciences, Inc., Thermo Fisher Scientific, Inc, Oxford Gene Technology Ip Ltd, Vitrolife AB, California Cryobank, Hamilton Thorne Inc., Merck KGaA, CooperSurgical Inc. and OvaScience Inc.

Key Developments:

In November 2023, Apollo Hospitals Enterprise Limited will invest around Rs 3,435 crore over the next three years to add 2,300 beds in metros and major cities in different parts of the country. The leading healthcare chain is also looking at Operations and Management agreements overseas in Indonesia and Tanzania, though it will not be investing for the purpose.

In November 2023, Japanese conglomerate Fujifilm Holdings Corp and US pharma giant Bristol Myers Squibb Co have agreed to buy the entire output of a 270-MW solar project being developed by National Grid Renewables in Texas. Each of the two companies has sealed virtual power purchase agreements (PPAs) with the Minneapolis, Minnesota-based renewable energy developer, the latter said on Wednesday.

In October 2023, INVO Bioscience, Inc., a healthcare services company focused on expanding access to advanced fertility treatment worldwide, and NAYA Biosciences Inc., a company dedicated to increasing patient access to breakthrough treatments in oncology and regenerative medicine, today jointly announced that they have entered into a definitive merger agreement for INVO to acquire NAYA Biosciences in an all-stock transaction.

Products Covered:

• Instrument
• Accessory & Disposable
• Reagents & Media
• Other Products

Procedures Covered:

• Fresh Donor
• Fresh Nondonor
• Frozen Donor
• Frozen Nondonor
• Embryo/Egg Banking
• Other Procedures

Technologies Covered:

• In Vitro-fertilization (IVF)
• Artificial Insemination - Intrauterine Insemination (AI-IUI)
• Frozen Embryo Replacement (FER)
• Surrogacy
• Ovulation Induction
• Other Technologies

End Users Covered:

• Hospital
• Fertility Clinics
• Surgical Center
• Clinical Research Institutes
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Technology Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Assisted Reproductive Technology (ART) Market, By Product

• 5.1 Introduction
• 5.2 Instrument
  • 5.2.1 Sperm Separation System
  • 5.2.2 Cryosystem
  • 5.2.3 Incubator
  • 5.2.4 Imaging System
  • 5.2.5 Ovum Aspiration Pump
  • 5.2.6 Cabinet
  • 5.2.7 Micromanipulator
  • 5.2.8 Laser Systems
• 5.3 Accessory & Disposable
• 5.4 Reagents & Media
  • 5.4.1 Cryopreservation Media
  • 5.4.2 Semen Processing Media
  • 5.4.3 Ovum Processing Media
  • 5.4.4 Embryo Culture Media
• 5.5 Other Products

6 Global Assisted Reproductive Technology (ART) Market, By Procedure

• 6.1 Introduction
• 6.2 Fresh Donor
• 6.3 Fresh Nondonor
• 6.4 Frozen Donor
• 6.5 Frozen Nondonor
• 6.6 Embryo/Egg Banking
• 6.7 Other Procedures

7 Global Assisted Reproductive Technology (ART) Market, By Technology

• 7.1 Introduction
• 7.2 In Vitro-fertilization (IVF)
  • 7.2.1 IVF with Intracytoplasmic Sperm Injection (ICSI)
  • 7.2.2 IVF without ICSI
• 7.3 Artificial Insemination - Intrauterine Insemination (AI-IUI)
• 7.4 Frozen Embryo Replacement (FER)
• 7.5 Surrogacy
• 7.6 Ovulation Induction
• 7.7 Other Technologies

8 Global Assisted Reproductive Technology (ART) Market, By End User

• 8.1 Introduction
• 8.2 Hospital
• 8.3 Fertility Clinics
• 8.4 Surgical Center
• 8.5 Clinical Research Institutes
• 8.6 Other End Users

9 Global Assisted Reproductive Technology (ART) Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Ferring B.V.
• 11.2 Apollo Hospitals Enterprise Ltd.
• 11.3 INVO Bioscience
• 11.4 Laboratoire CCD
• 11.5 Nidacon International AB
• 11.6 Fujifilm Holdings Corporation
• 11.7 Bloom Fertility Centre
• 11.8 Inception Sciences, Inc.
• 11.9 Thermo Fisher Scientific, Inc
• 11.10 Oxford Gene Technology Ip Ltd
• 11.11 Vitrolife AB
• 11.12 California Cryobank
• 11.13 Hamilton Thorne Inc.
• 11.14 Merck KGaA
• 11.15 CooperSurgical Inc.
• 11.16 OvaScience Inc.